AnaBios, a San Diego, CA-based biotechnology company advancing drug development through its proprietary Phase X technology, raised $10m in Series B funding.
Backers included Principia, a Milan, Italy based venture capital firm which specializes in Healthcare and Medical Device, which made a €4m investment.
The company intends to use the funds to expand contract research capabilities and accelerate the development of the its own drug programs.
Led by Andre Ghetti, Ph.D., Chief Executive Officer, AnaBios advances drug development through proprietary Phase X technology focusing on therapeutic areas of major unmet medical need such as pain, cardiac disease and neurodegenerative diseases. In addition, the company’s technology has the potential to assess drug safety at the preclinical stage via generation of human relevant data, thereby reducing clinical stage failures.
AnaBios currently offers drug discovery services to major pharmaceutical companies in the USA, Europe, Japan and Korea, and also conducts its own drug discovery in pain and heart disease.